Bayer lifts peak sales estimate for prostate cancer drug
Bayer lifts peak sales estimate for prostate cancer drug
February 18, 2022; 3:34 AM EST
Bayer lifts peak sales estimate for prostate cancer drug
February 18, 2022; 3:34 AM EST
FRANKFURT, Feb 18 (Reuters) – A therapy mix including Bayer’s (BAYGn.DE) Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the drugmaker to boost sales estimates for the product.
Nubeqa, when combined with standard therapy, reduced the risk of dying during the trial period by 32.5% in a comparison to standard therapy alone, the German company said in a statement on Thursday, citing trial results.
As a result, Bayer said it now expected more than 3 billion euros ($3.4 billion) in sales from the product in its best year, up from a previous target of more than $1 billion, making Nubeqa the most promising growth driver at Bayer’s drugs division.
Nubeqa, also known as darolutamide, is jointly developed with Finnish drugmaker Orion (ORNBV.HE) and the partner company’s stock soared 22.7% at the 0800 GMT market open, while Bayer shares gained 1.9%.
Bayer, which is paying billions to settle U.S. claims its Roundup weedkiller caused cancer, needs to strengthen its drug development pipeline as its two pharmaceutical best-sellers, stroke prevention pill Xarelto and eye drug Eylea, face a decline in sales in a few years.
Nubeqa is already approved in non-metastatic prostate cancer that cannot be treated with standard hormone therapy, and the new results point to a larger market opportunity if regulators clear the wider use.
The drug is one of three Bayer pharmaceuticals that the company expects to generate more than $1 billion in peak annual sales, known in the industry as blockbusters, alongside kidney disease treatment finerenone and menopausal symptoms relief elinzanetant.
The trial’s overall success was announced in December and detailed results were published in The New England Journal of Medicine on Thursday. read more
($1 = 0.8797 euros)
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: